


## MK-4256

- Developed as a treatment for type two diabetes.
- If left untreated or not managed properly can cause diabetic retinopathy or neuropathy.
- Targets the protein SSTR3, which is one of the proteins that mediate somatostatin.
- Somatostatin is known to suppress production of insulin, making it a potential target. Therefore, antagonism of this protein has potential to promote glucose dependent insulin secretion.




MK-4256




ACS Med. Chem. Lett. **2012**, 3, 484–489 <https://doi.org/10.1021/ml300063m>

## Initial scaffold optimization




## Retrosynthesis




Org. Process Res. Dev. **2012**, 16, 1329–1337 <https://doi.org/10.1021/op300128c>


## Synthesis of heterocycle




## Pictet-Spengler




## Process Route



- While the iodopyrazole was purchased for the discovery route, it was found to be significantly cheaper to start from N-methylpyrazole (\$956 per kg) vs. 4-iodo-N-methylpyrazole (\$3360 per kg).



- Switching to ethyl ester was found to allow for an easier isolation of the potassium salt, after hydrolysis.
- While the yield of the 1,2 addition into Weinreb amide was quite low, only a change in the work up procedure (switching from EtOAc to DCM) followed by a recrystallization gave a massive improvement in the yield.



- The  $\alpha$ -bromo ketone was not available in large enough quantities to support multi kilogram preparation of MK-4256.

